Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 11/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4277869 | 0.78 | L3MBTL1 (0.47) | ALOX15L3MBTL1ALDH1A1KDM4EGAA | |
| SCHEMBL1820360 | 0.78 | SLC6A9 (0.44) | SLC6A9 | |
| SCHEMBL1819806 | 0.77 | SLC6A9 (0.37) | SLC6A9ALOX15L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL178417 | 0.76 | L3MBTL1 (0.49) | ALOX15L3MBTL1ALDH1A1KDM4EGAA | |
| SCHEMBL14417825 | 0.73 | L3MBTL1 (0.44) | SLC6A9ALOX15L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL31030375 | 0.72 | L3MBTL1 (0.49) | ALOX15L3MBTL1ALDH1A1KDM4EGAA | |
| SCHEMBL23555007 | 0.72 | L3MBTL1 (0.56) | L3MBTL1ALDH1A1KDM4EGAAPKM | |
| SCHEMBL14417817 | 0.70 | L3MBTL1 (0.45) | SLC6A9ALOX15L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL5504640 | 0.70 | ALDH1A1 (0.46) | SLC6A9L3MBTL1ALDH1A1KDM4EGLA | |
| SCHEMBL14836301 | 0.69 | SLC6A9 (0.54) | SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947714-B2 | Piperidine glycine transporter inhibitors | Merck, Sharp & Dohme Corp. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20090270451-A1 | Piperdine Glycine Transporter Inhibitors | MERCK & CO., INC. (US) | 2009-10-29 | — | — | US | disclosed |
| EP-1942893-A2 | PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | Merck & Co., Inc. (US) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007053400-A2 | PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK & CO., INC. (US) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270451-A1 | Piperdine Glycine Transporter Inhibitors | SLC1A2, SLC1A1, SLC1A3 | SLC6A9 19/4885ALOX15 3469/4885L3MBTL1 1881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.